Key result
Heart failure and osteoporosis share bidirectional links, warranting integrated clinical management in aging patients.
Why the study?
Heart failure and osteoporosis commonly co-occur with poor prognosis, but the details of their shared pathophysiological relationship have yet to be revealed.
What are the shared pathophysiological mechanisms, risk factors, and potential therapeutic targets for coexisting heart failure and osteoporosis?
What are the shared pathophysiological mechanisms, risk factors, and potential therapeutic targets for coexisting heart failure and osteoporosis?
Recognizing the reciprocal interactions between heart failure and osteoporosis highlights the need for a holistic, integrated treatment approach to improve the prognosis in the aging population.
In clinical practice, heart failure (HF) and osteoporosis (OP) are commonly paired conditions. This association is particularly relevant in patients over the age of 50, among whom its prevalence increases dramatically with every decade of life. This can be especially impactful since patient prognosis when facing both conditions is poorer than that of each disease alone. Clinical studies suggest that prior fractures increase the risk for heart failure hospitalization and, conversely, an episode of heart failure increases the risk of subsequent fractures. In other words, the relationship between osteoporosis and heart failure seems to be two-way, meaning that each condition may influence or contribute to the development of the other. However, the details of the pathophysiological relationship between HF and OP have yet to be revealed. The two conditions share multiple pathological mechanisms that seem to be intertwined. Patients affected by OP are more prone to develop HF because of vitamin D deficiency, elevation of parathyroid hormone (PTH) plasma levels, and increased Fibroblast Growth Factor 23 (FGF-23) activity. On the other hand, HF patients are more prone to develop OP and pathological fractures because of low vitamin D level, high PTH, chronic renal failure, alteration of renin-angiotensin-aldosterone system, reduced testosterone level, and metabolic effects derived from commonly used medications. Considering the increasingly aging worldwide population, clinicians can expect to see more often an overlap between these two conditions. Thus, it becomes crucial to recognize how HF and OP mutually influence the patient's clinical condition. Clinicians attending these patients should utilize an integrated approach and, in order to improve prognosis, aim for early diagnosis and treatment initiation. The aim of this paper is to perform a review of the common pathophysiological mechanisms of OP and HF and identify potentially new treatment targets.
No takes yet. Share an insight, caveat, or question.
Spoladore et al. (2025) conducted a review in Heart Failure and Osteoporosis. Coexisting heart failure and osteoporosis was evaluated. Heart failure and osteoporosis share bidirectional pathophysiological mechanisms and risk factors, necessitating integrated clinical management and early treatment in the aging population.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: